Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Prostate Cancer

  Free Subscription


3 BJU Int
1 BMC Cancer
1 BMC Urol
1 Cancer
2 Cancer Res
1 Clin Cancer Res
3 Eur Urol
2 Int J Urol
2 Invest Radiol
1 J Magn Reson Imaging
3 J Urol
2 Prostate
1 Radiology
2 Urology

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    BJU Int

  1. EMMETT L, Subramaniam S, Joshua A, Crumbaker M, et al
    ENZA-p trial protocol: A randomised phase II trial using PSMA as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
    BJU Int. 2021 May 24. doi: 10.1111/bju.15491.
    PubMed         Abstract available

  2. MEIJER D, van Leeuwen PJ, Donswijk ML, Boellaard TN, et al
    Predicting Early Outcomes in Intermediate and High Risk Prostate Cancer Patients using PSMA PET and MRI.
    BJU Int. 2021 May 24. doi: 10.1111/bju.15492.
    PubMed         Abstract available

  3. KNIPPER S, Tilki D, Graefen M, Maurer T, et al
    Early prostate cancer recurrence with PSMA PET positive unilateral pelvic lesion(s): is one-sided salvage extended lymph node dissection enough? (ProSTone, NCT04271579).
    BJU Int. 2021 May 22. doi: 10.1111/bju.15485.
    PubMed         Abstract available

    BMC Cancer

  4. OKAMOTO T, Noro D, Hatakeyama S, Narita S, et al
    Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study.
    BMC Cancer. 2021;21:605.
    PubMed         Abstract available

    BMC Urol

  5. KIM WT, Kang HW, Seo SP, Kim YJ, et al
    Effect of pre-operative internal obturator muscle mass index in MRI on biochemical recurrence of prostate cancer patients after radical prostatectomy: a multi-center study.
    BMC Urol. 2021;21:85.
    PubMed         Abstract available


  6. HUNT TC, Ambrose JP, Haaland B, Kawamoto K, et al
    Decision fatigue in low-value prostate cancer screening.
    Cancer. 2021 May 27. doi: 10.1002/cncr.33644.
    PubMed         Abstract available

    Cancer Res

  7. MATSUSHITA M, Fujita K, Hayashi T, Kayama H, et al
    Gut microbiota-derived short-chain fatty acids promote prostate cancer growth via IGF-1 signaling.
    Cancer Res. 2021 May 26. pii: 0008-5472.CAN-20-4090.
    PubMed         Abstract available

  8. OSMULSKI PA, Cunsolo A, Chen M, Qian Y, et al
    Contacts with macrophages promote an aggressive nanomechanical phenotype of circulating tumor cells in prostate cancer.
    Cancer Res. 2021 May 27. pii: 0008-5472.CAN-20-3595.
    PubMed         Abstract available

    Clin Cancer Res

  9. HAMMER S, Schlicker A, Zitzmann-Kolbe S, Baumgart S, et al
    Darolutamide potentiates the antitumor efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC) by a dual mode-of-action in prostate cancer models.
    Clin Cancer Res. 2021 May 25. pii: 1078-0432.CCR-21-0342.
    PubMed         Abstract available

    Eur Urol

  10. SWEENEY CJ, Martin AJ, Stockler MR, Begbie S, et al
    Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.
    Eur Urol. 2021 May 21. pii: S0302-2838(21)00354.
    PubMed         Abstract available

  11. RAJWA P, Pradere B, Quhal F, Mori K, et al
    Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis.
    Eur Urol. 2021 May 18. pii: S0302-2838(21)00325.
    PubMed         Abstract available

  12. XU J, Isaacs WB
    Incorporation of Polygenic Risk Score into Guidelines for Inherited Risk Assessment for Prostate Cancer.
    Eur Urol. 2021 May 20. pii: S0302-2838(21)00323.

    Int J Urol

  13. CHIKAMATSU S, Shiota M, Onozawa M, Hinotsu S, et al
    Dynamics of conditional survival and risk factors in androgen deprivation therapy for prostate cancer using a multi-institutional Japan-wide database.
    Int J Urol. 2021 May 24. doi: 10.1111/iju.14605.
    PubMed         Abstract available

  14. STOLZENBACH LF, Deuker M, Colla-Ruvolo C, Nocera L, et al
    Radical prostatectomy improves survival in selected metastatic prostate cancer patients: A North American population-based study.
    Int J Urol. 2021 May 28. doi: 10.1111/iju.14586.
    PubMed         Abstract available

    Invest Radiol

  15. MAKOWSKI MR, Bressem KK, Franz L, Kader A, et al
    De Novo Radiomics Approach Using Image Augmentation and Features From T1 Mapping to Predict Gleason Scores in Prostate Cancer.
    Invest Radiol. 2021 Apr 22. doi: 10.1097/RLI.0000000000000788.
    PubMed         Abstract available

  16. LANGBEIN BJ, Szczepankiewicz F, Westin CF, Bay C, et al
    A Pilot Study of Multidimensional Diffusion MRI for Assessment of Tissue Heterogeneity in Prostate Cancer.
    Invest Radiol. 2021 May 27. pii: 00004424-900000000-98695.
    PubMed         Abstract available

    J Magn Reson Imaging

  17. NKETIAH GA, Bathen TF
    Editorial for "MRI Radiomics-Based Machine Learning for Predict of Clinically Significant Prostate Cancer in Equivocal PI-RADS 3 Lesions".
    J Magn Reson Imaging. 2021 May 27. doi: 10.1002/jmri.27752.

    J Urol

  18. LIFSHITZ K, Ber Y, Shenhar C, Nillson J, et al
    Cardiovascular Proteomics: A Post-hoc Analysis from a Phase II Randomized Clinical Trial Comparing GnRH Antagonist Vs GnRH Agonist Among Men with Advanced Prostate Cancer.
    J Urol. 2021 May 25:101097JU0000000000001879. doi: 10.1097/JU.0000000000001879.
    PubMed         Abstract available

  19. AGARWAL N, McQuarrie K, Bjartell A, Chowdhury S, et al
    Apalutamide Plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study.
    J Urol. 2021 May 27:101097JU0000000000001841. doi: 10.1097/JU.0000000000001841.
    PubMed         Abstract available

  20. CHEUNG DC, Alibhai SMH, Martin LJ, Komisarenko M, et al
    Real World Practice Patterns and Predictors of Continuous versus Intermittent ADT Use for Prostate Cancer in Older Men.
    J Urol. 2021 May 25:101097JU0000000000001876. doi: 10.1097/JU.0000000000001876.
    PubMed         Abstract available


  21. ZHU S, Chen J, Ni Y, Zhang H, et al
    Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patients.
    Prostate. 2021 May 24. doi: 10.1002/pros.24167.
    PubMed         Abstract available

  22. MISHRA A, Zennami K, Velarde E, Thorek DLJ, et al
    Longitudinal measurement of subcutaneous and intratibial human prostate cancer xenograft growth and response to ionizing radiation by plasma Alu and LINE-1 ctDNA: A comparison to standard methods.
    Prostate. 2021 May 25. doi: 10.1002/pros.24171.
    PubMed         Abstract available


  23. DENIFFEL D, Healy GM, Dong X, Ghai S, et al
    Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer.
    Radiology. 2021 May 25:204112. doi: 10.1148/radiol.2021204112.
    PubMed         Abstract available


  24. KING MC, Sardi A, Velez-Mejia C, Sittig M, et al
    Novel Case of Isolated Peritoneal Carcinomatosis from Metastatic Prostate Cancer Carrying a Pathogenic BRCA Mutation Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Urology. 2021 May 25. pii: S0090-4295(21)00435.
    PubMed         Abstract available

  25. ARMSTRONG N, Bahl A, Pinkawa M, Ryder S, et al
    SpaceOAR Hydrogel spacer for reducing radiation toxicity during radiotherapy for prostate cancer. A systematic review.
    Urology. 2021 May 22. pii: S0090-4295(21)00421.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.